Search - tctmd.com

Displaying 1 - 20 of 26

Sort: Relevancy | Date

News Conference News TCT 2025

DOAC May Be Safer Than DAPT After Left Atrial Appendage Closure: ANDES

Yael L. Maxwell

November 04, 2025

News Conference News TCT 2023

LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI

L.A. McKeown

October 25, 2023

News Conference News TCT 2022

RIVARAD: Rivaroxaban a Possible Solution to Radial Artery Occlusion

Todd Neale

September 21, 2022

Presentation TCT 2022

Prevention of Radial Artery Occlusion With Rivaroxaban After Transradial Coronary Procedures: The RIVARAD Multicentric Randomized Trial

Presenter: Rania Hammami

September 19, 2022

News Conference News TCT 2022

As Time Goes By, Post-TAVI Thrombus Becomes More OAC Resistant

Michael O'Riordan

September 18, 2022

News Conference News TCT 2020

IN.PACT BTK Provides Renewed Hope for Attacking CLI With DCBs

L.A. McKeown

October 18, 2020

News Conference News TCT 2019

Oral Anticoagulation After TAVR Doesn’t Reduce Ischemic Cerebral Lesions: AUREA

Michael O'Riordan

September 28, 2019

News Conference News TCT 2019

Leaflet Thickening and Impaired Motion No Worse With TAVR: PARTNER 3 CT

Michael O'Riordan

September 27, 2019

News Conference News TCT 2019

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

Todd Neale

September 26, 2019

News Conference News TCT 2019

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

Yael L. Maxwell

September 26, 2019

News Conference News TCT 2018

More GLOBAL LEADERS: No Benefit of Ticagrelor Monotherapy in New Analyses

Michael O'Riordan

September 24, 2018

Presentation TCT 2018

COMPASS Trial Revisited: Weighing Rivaroxaban Secondary Prevention vs DAPT After PCI

Presenter: Deepak L. Bhatt, Tullio Palmerini, Michael Maeng

September 23, 2018

Presentation TCT 2017

The PIONEER Trial: Rivaroxaban in Patients With ACS and Atrial Fibrillation - Are the Results Enough to Change Practice?

Presenter: Deepak L. Bhatt, C. Michael Gibson

November 01, 2017

Presentation TCT 2016

The PIONEER Trial: Rivaroxaban in Patients With ACS and Atrial Fibrillation: Design, Rationale, and Status

Presenter: Freek W.A. Verheugt, Pascal Vranckx, C. Michael Gibson

November 01, 2016

Presentation TCT 2015

The PIONEER Trial (Rivaroxaban in Patients With ACS and Atrial Fibrillation): Design, Rationale, and Status

Presenter: Pascal Vranckx, Roxana Mehran

October 14, 2015

Presentation TCT 2015

Rivaroxaban: Analysis of Efficacy, Safety, and Special Considerations

Presenter: Lisa K. Jennings, Matthew T. Roe, Manesh R. Patel

October 14, 2015

News Conference News TCT 2014

Thoughtful Insights at TCT: Uncertainty Surrounds Antithrombotic Therapy in PCI Patients Who Require Anticoagulation

Todd Neale

October 10, 2014

Presentation TCT 2014

Rivaroxaban in ACS and Atrial Fibrillation: Randomized Trials, Real-World Data, and Pioneering Efforts

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson

September 15, 2014

Presentation TCT 2013

Potential for Rivaroxaban Use in ACS and in the PCI Patient: Why Different Interpretations of the Same Data in the US and Europe?

Presenter: C. Michael Gibson

October 31, 2013

Presentation TCT 2013

Case Presentation: A Patient With Atrial Fibrillation on Rivaroxaban Who Develops a STEMI

Presenter: E. Magnus Ohman

October 31, 2013

Advertisement

DOAC May Be Safer Than DAPT After Left Atrial Appendage Closure: ANDES

LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI

RIVARAD: Rivaroxaban a Possible Solution to Radial Artery Occlusion

Prevention of Radial Artery Occlusion With Rivaroxaban After Transradial Coronary Procedures: The RIVARAD Multicentric Randomized Trial

As Time Goes By, Post-TAVI Thrombus Becomes More OAC Resistant

IN.PACT BTK Provides Renewed Hope for Attacking CLI With DCBs

Oral Anticoagulation After TAVR Doesn’t Reduce Ischemic Cerebral Lesions: AUREA

Leaflet Thickening and Impaired Motion No Worse With TAVR: PARTNER 3 CT

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

More GLOBAL LEADERS: No Benefit of Ticagrelor Monotherapy in New Analyses

COMPASS Trial Revisited: Weighing Rivaroxaban Secondary Prevention vs DAPT After PCI

The PIONEER Trial: Rivaroxaban in Patients With ACS and Atrial Fibrillation - Are the Results Enough to Change Practice?

The PIONEER Trial: Rivaroxaban in Patients With ACS and Atrial Fibrillation: Design, Rationale, and Status

The PIONEER Trial (Rivaroxaban in Patients With ACS and Atrial Fibrillation): Design, Rationale, and Status

Rivaroxaban: Analysis of Efficacy, Safety, and Special Considerations

Thoughtful Insights at TCT: Uncertainty Surrounds Antithrombotic Therapy in PCI Patients Who Require Anticoagulation

Rivaroxaban in ACS and Atrial Fibrillation: Randomized Trials, Real-World Data, and Pioneering Efforts

Potential for Rivaroxaban Use in ACS and in the PCI Patient: Why Different Interpretations of the Same Data in the US and Europe?

Case Presentation: A Patient With Atrial Fibrillation on Rivaroxaban Who Develops a STEMI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content